Pasithea Therapeutics begins dosing cohort 2 in Phase 1 trial of PAS-004
PremiumThe FlyPasithea Therapeutics begins dosing cohort 2 in Phase 1 trial of PAS-004
3M ago
Pasithea Therapeutics to present cancer study data showing PAS-004 efficacy
Premium
The Fly
Pasithea Therapeutics to present cancer study data showing PAS-004 efficacy
4M ago
Pasithea completes initial dosing in first cohort of Phase 1 PAS-004 trial
Premium
The Fly
Pasithea completes initial dosing in first cohort of Phase 1 PAS-004 trial
5M ago
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
PremiumPress ReleasesPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
9M ago
Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004
Premium
The Fly
Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004
9M ago
Pasithea Therapeutics Corp trading halted, news pending
Premium
The Fly
Pasithea Therapeutics Corp trading halted, news pending
9M ago
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
PremiumPress ReleasesPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
10M ago
Pasithea Therapeutics announces outcome of pre-IND meeting for PAS-004
Premium
The Fly
Pasithea Therapeutics announces outcome of pre-IND meeting for PAS-004
10M ago
Pasithea Therapeutics selects PAS-003 lead development candidate
Premium
The Fly
Pasithea Therapeutics selects PAS-003 lead development candidate
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100